Trial Details

Recruiting
Basic Information
Clinical ID c5442
Identifier ACTRN12621001498886
Trial Title Comparison between switching from intravenous to subcutaneous infliximab on the maintenance of clinical and biochemical remission in patients with inflammatory bowel disease
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Ulcerative colitis;Crohn's disease; Ulcerative colitis Crohn's disease;Inflammatory and Immune System - Autoimmune diseases;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions Intervention - switching patients from intravenous infliximab to subcutaneous infliximab for the treatment of inflammatory bowel disease- subcutaneous infliximab: administered via a pre-filled syringe at a dose of 120mg subcutaneously every 2 weeks<br
Participant Information
Sponsor Concord Repatriation General Hospital
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase PHASE4
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL